From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2016 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“必须说服买家考虑”转变为“在买家自己的采购、报销、处方集、规格、采购、网络、目录或计划系统中获得批准、指定、列入、合格、注册、报销或预先授权”的选择,从而使得公司未来业务的很大一部分可以在没有每次单独销售事件的情况下到来,并且管理层是否传达了这种准入状态是新的,以至于它解锁的大部分数量仍领先于报告的结果。 在记录中,管理层讨论了各种产品批准和订单,但我们需要寻找的是公司被纳入买家系统(如批准供应商名单、采购计划、报销途径等)的具体描述,并且这种状态是新的,尚未完全反映在结果中。 检查记录: - 提到了Radixact平台获得FDA 510(k)批准,但这是产品批准,不是被纳入买家系统。 - 提到了Onrad系统获得中国CFDA批准,但同样,这是产品批准,不是被纳入买家系统。 - 提到了NHS订单,但那是单个订单,不是系统性的纳入。 - 没有提到公司被列入任何批准供应商名单、采购计划、报销目录等。 管理层确实提到了“多系统订单”和“战略账户”,但这些都是销售活动,不是系统性的准入。 因此,没有证据表明公司最近获得了这种“默认”地位。答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.